Positively Sharing

Alzheimer’s drugs ‘make no meaningful difference to patients’, say researchers

Reading Time: minute

Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer’s (Alamy/PA) -

Drugs that are said to slow the progression of Alzheimer’s disease “make no meaningful difference to patients” while increasing the risk of swelling and bleeding  Read More

Exit mobile version